All Oncology News

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

The future looks bright for immunotherapies and novel targeted approaches for patients with gliomas, many of which have already been developed for other types of cancer.

Immunotherapy should be considered along with VEGF and mTOR TKIs as a highly effective treatment modality for patients with metastatic renal cell carcinoma.

Colin Weekes, MD, PhD, gives insight into the current state and future directions for neoadjuvant therapy for pancreatic cancer.

Biologic chemotherapy spending soared several hundred percent from 2004 to 2014; but despite rising treatment costs in general, oncology spending kept pace with spending for all categories of medical care.

Eribulin mesylate (Halaven) has received a positive recommendation from the EMA’s Committee for Medicinal Products for Human Use as a treatment for patients with advanced or unresectable liposarcoma following prior treatment with an anthracycline-based chemotherapy.

Tara C. Mitchell, MD, discusses what oncologists need to know about using immunotherapies in melanomaâ€â€

Sundar Jagannath, MD, discusses emerging agents in multiple myeloma he is most excited about, sequencing challenges, and the role for personalized medicine in the disease.

Collaboration to promote cancer center's advances in cancer research and treatment.

Sarah Goldberg, MD, MPH, discusses the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with non–small cell lung cancer.

Many patients with metastatic colorectal cancer will ultimately progress on standard first- and second-line therapy while maintaining a good performance status, placing importance on the optimal use of third-line treatments.

Single-agent daratumumab (Darzalex) for the treatment of patients with relapsed/refractory multiple myeloma previously treated with a proteasome inhibitor and an immunomodulatory agent has received a positive recommendation from the Committee for Medicinal Products for Human Use.

A bevy of clinical trials exploring the use of nab-paclitaxel (Abraxane) in various combinations and treatment settings aim to uncover future strategies for treating patients with pancreatic adenocarcinoma, which remains one of the deadliest forms of cancer.

Carol Rossier Bradford, MD, discusses the treatment and surgical outlook for head and neck melanoma, as well as other subtypes of the disease.

Michael Davies, MD, discusses the biggest challenges in treating brain metastases, what is known about the connection to the PI3K/AKT pathway, and what his future plans are for research in this area.

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

Adding plitidepsin (Aplidin) to dexamethasone reduced the risk of disease progression by 35% versus dexamethasone alone in patients with relapsed/refractory multiple myeloma enrolled in the phase III ADMYRE trial.

The MEK inhibitor binimetinib failed to improve progression-free survival compared with physician's choice of chemotherapy for patients with low-grade serous ovarian cancer.

The combination of ipilimumab and nivolumab has received a positive recommendation from the CHMP, which suggests that the treatment is likely to gain European approval for patients with advanced melanoma.

A new drug application has been submitted to the FDA for telotristat etiprate as a treatment for carcinoid syndrome in patients with metastatic neuroendocrine tumors.

The European Medicines Agency validated an application for use of nivolumab (Opdivo) for previously treated patients with classical Hodgkin lymphoma), which officially begins the centralized review process for final approval of the drug in the European Union.

Adding daratumumab (Darzalex) to standard bortezomib (Velcade) and dexamethasone improved progression-free survival in patients with relapsed/refractory multiple myeloma enrolled in the phase III CASTOR (MMY3004) trial.

Puma Biotechnology announced that it plans to delay the submission of a new drug application until mid-2016 for neratinib as an extended adjuvant treatment for patients with HER2-positive early breast cancer following a trastuzumab-based regimen.

The FDA has approved defibrotide sodium as a treatment for severe hepatic veno-occlusive disease with associated kidney or lung abnormalities following hematopoietic stem cell transplantation.

Renewing a commitment to advance its reputation in lung cancer and other thoracic malignancies, NYU Langone Medical Center has announced the appointment of physician-scientist Leena Gandhi, MD, PhD, as director of thoracic medical oncology at its Laura and Isaac Perlmutter Cancer Center.

Treatment with gefitinib failed to show noninferiority compared with erlotinib for patients with pretreated non–small cell lung cancer.

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Lenalidomide (Revlimid) was found to significantly increase progression-free survival in patients with relapsed/refractory mantle cell lymphoma when compared with investigator's choice of single-agent therapy.

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Erika P. Hamilton, MD, discusses the significance of these trials and the impact ONT-380 may have on the treatment paradigm of HER2-positive breast cancer.